CRISPR/Cas Tau Biosensor Screening for Aggregation Modifiers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for identifying genetic modifiers of tau aggregation, which is a key factor in neurodegenerative diseases such as Alzheimer's and Parkinson's, as they do not effectively screen for genes that enhance or inhibit this process.
Innovation Solution
A CRISPR/Cas-based screening platform is developed to identify genetic modifiers of tau aggregation by using cells with tau repeat domains linked to reporters, introducing guide RNAs to edit genes, and culturing them with tau seeding agents to form aggregates, allowing for the enrichment of guide RNAs that indicate genetic modifiers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current screening methods are used, then the process is simpler, but the ability to identify genetic modifiers of tau aggregation is inadequate
Solution Approach 1:
The screening platform is segmented into distinct functional modules: CRISPR/Cas9 genome editing system, tau aggregation assay system with fluorescent reporters, and high-throughput sequencing system. Each module performs a specific function (gene knockout, aggregation detection, data analysis) allowing the complex screening process to be managed through modular components that can be independently optimized and validated
Solution Approach 2:
Fluorescent reporter proteins (e.g., GFP, mCherry) serve as intermediaries that convert the biological process of tau aggregation into quantifiable optical signals. These reporters bind to or are expressed with tau proteins, allowing indirect but highly sensitive detection of aggregation events that would otherwise be difficult to measure at single-cell resolution
2Adaptability or versatility
If a comprehensive library of guide RNAs is introduced, then more genes can be screened, but the culture and analysis process becomes more complex
Solution Approach 1:
The screening platform uses a universal guide RNA library design that can target any gene in the genome through the CRISPR/Cas9 system. The same basic assay protocol (transduction, culturing, aggregation detection, sequencing) applies regardless of which specific genes are being screened, allowing comprehensive genome-wide screening without proportionally increasing operational complexity
Solution Approach 2:
High-throughput sequencing provides quantitative feedback on guide RNA abundance in aggregated versus non-aggregated cell populations. This feedback is processed through bioinformatic pipelines that automatically identify enriched guide RNAs, calculate enrichment scores, and prioritize candidate genes, converting complex raw data into actionable insights with minimal manual intervention
3Reliability
If tau aggregation is allowed to form in cultured cells, then genetic modifiers can be identified, but the time required for aggregation to occur increases screening duration
Solution Approach 1:
Cells are pre-transduced with guide RNAs and allowed to express CRISPR/Cas9 and undergo initial genome editing before being subjected to tau aggregation conditions. This preliminary genome editing phase ensures that genetic modifications are established prior to the aggregation assay, preventing confounding effects of simultaneous gene editing and aggregation that could compromise assay validity
Solution Approach 2:
The aggregation assay optimizes multiple parameters including tau protein expression levels, seeding agent concentrations, cell density, and incubation temperatures to accelerate aggregation kinetics. By tuning these parameters, the system achieves reliable aggregation within reduced timeframes while maintaining physiological relevance of the aggregation process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform efficiently identifies genes that enhance or inhibit tau aggregation, providing valuable insights into disease mechanisms and potential therapeutic targets.
Implementation Method 1
the plurality of unique guide RNAs form complexes with the Cas protein, and the Cas protein cleaves the plurality of genes resulting in knockout of gene function
Implementation Method 2
aggregates of the first tau repeat domain and the second tau repeat domain form in a subset of the seeded population of cells
Data Source
AI summary
Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.